Smac Mimetic Therapy
A Smac mimetic therapy wherein the Smac mimetic is selected and developed based at least in part on its poor inhibition of XIAP-dependent processes.
1 . A business method for marketing a Smac mimetic for use in the treatment of a proliferative disorder to one or more of healthcare providers, patients, and insurance providers, which method comprises informing one or more of healthcare providers, patients, and insurance providers that the Smac mimetic has been shown by testing not to inhibit XIAP-dependent processes or to inhibit XIAP-dependent processes poorly.
2 . A method of treating a patient suffering from a proliferative disorder that comprises the steps of (1) screening a Smac mimetic for inhibition of XIAP-dependent processes and (2) if the Smac mimetic does not inhibit XIAP XIAP-dependent processes or only poorly inhibits XIAP XIAP-dependent processes, then internally administering an effective amount of the Smac mimetic to the patient.
3 . A method of screening and selecting Smac mimetics for clinical development and commercialization that comprises screening candidate Smac mimetics for inhibition of XIAP XIAP-dependent processes and selecting for and utilizing in clinical development candidate Smac mimetics that do not inhibit XIAP XIAP-dependent processes or inhibit XIAP XIAP-dependent processes poorly.
4 . A method of commercializing a Smac mimetic that comprises testing a Smac mimetic for inhibition of XIAP XIAP-dependent processes and if the Smac mimetic does not inhibit XIAP XIAP-dependent processes or only poorly inhibits XIAP XIAP-dependent processes, then informing healthcare providers, patients, or insurance providers that the Smac mimetic has been shown not to inhibit XIAP XIAP-dependent processes or to inhibit XIAP XIAP-dependent processes poorly.
5 . The method of claim 1 wherein the testing or screening for inhibition of XIAP-dependent processes comprises assaying for (i) inhibition of NOD1/2 signaling, (ii) induction of IL-1β secretion, or (iii) both (i) and (ii).
6 . The method of claim 5 where the Smac mimetic is also tested or screened for affinity for or degradation of cIAP1, cIAP2, and XIAP and is shown to have or is selected based on having (i) greater affinity for cIAP1 than for XIAP and cIAP2, (ii) greater potency against cIAP2 relative to cIAP1, or (iii) both (i) and (ii).
7 . The method of claim 5 wherein:
(1) the assay for NOD1 signaling is a DAP-stimulated NF-B-reporter gene assay and wherein a Smac mimetic is determined not to inhibit XIAP E3 ligase activity or to inhibit XIAP E3 ligase activity poorly if reporter gene activity is inhibited by no more than about 50% by 10 uM Smac mimetic;
(2) the assay for NOD2 signaling is a MDP-stimulated NF-B-reporter gene assay and wherein a Smac mimetic is determined not to inhibit XIAP E3 ligase activity or to inhibit XIAP E3 ligase activity poorly if reporter gene activity is inhibited by no more than about 50% by 10 uM Smac mimetic;
(3) the assay for induction of IL-1β secretion is a cell based assay comprising XIAP +/+ cells and wherein a Smac mimetic is determined not to inhibit XIAP-dependent processes or to inhibit XIAP-dependent processes poorly if IL-1β secretion in cells treated with up to 1000 nM of the Smac mimetic is about the same as IL-1β secretion in untreated cells or in cells treated with LPS.
8 . The method of claim 5 wherein the Smac mimetic is dimeric with two functional IAP binding motifs and lacks a branched side chain in the P2 portions.
9 . The method of claim 8 wherein the two monomeric units of the dimeric Smac mimetic are linked through the P4 portions by a single covalent bond or by a linker that is two or fewer atoms long.